Erythropoiesis-stimulating agents for anemia in older adults

T. S. Dharmarajan, David Widjaja

Research output: Contribution to journalArticle

Abstract

Erythropoietin, a humoral factor produced predominantly in the kidney, stimulates red blood cell production in the bone marrow. Erythropoiesis-stimulating agents (ESAs) have been used for years in the treatment of anemia, with extensive experience and benefits in anemia of chronic kidney disease. Recent data have suggested adverse consequences with use of ESAs, perhaps relating to inappropriate use, and prompting release of guidelines to ensure safe use and maximize benefit. When prescribing ESAs, indications, requirements to monitor laboratory parameters (hemoglobin levels and ferrokinetics), and clinical status need to be stringently followed.

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalFormulary
Volume43
Issue number8
Publication statusPublished - Aug 1 2008
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this